NASDAQ:INO - Inovio Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.20
  • Forecasted Upside: 156.84 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.75
▲ +0.14 (3.04%)

This chart shows the closing price for INO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inovio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INO

Analyst Price Target is $12.20
▲ +156.84% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Inovio Pharmaceuticals in the last 3 months. The average price target is $12.20, with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 156.84% upside from the last price of $4.75.

This chart shows the closing price for INO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Inovio Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/30/2021Jefferies Financial GroupLower Price TargetHold$8.00 ➝ $6.00High
12/15/2021HC WainwrightReiterated RatingHoldHigh
11/1/2021Royal Bank of CanadaLower Price TargetSector Perform$7.00 ➝ $6.00High
9/10/2021Bank of AmericaDowngradeNeutral ➝ Underperform$9.00 ➝ $8.00High
7/2/2021OppenheimerReiterated RatingBuy$35.00N/A
6/24/2021Jefferies Financial GroupInitiated CoverageHold$9.00Medium
5/10/2021Piper SandlerLower Price TargetHold ➝ Neutral$7.00 ➝ $6.00High
4/16/2021HC WainwrightReiterated RatingHoldLow
4/16/2021OppenheimerReiterated RatingBuyLow
3/23/2021Bank of AmericaInitiated CoverageNeutral$13.00High
2/11/2021OppenheimerInitiated CoverageOutperform$35.00Low
1/8/2021BenchmarkLower Price TargetBuy$25.00 ➝ $15.00Medium
11/17/2020Roth CapitalDowngradeNeutral ➝ Sell$8.00Medium
11/10/2020Roth CapitalUpgradeSell ➝ Neutral$8.00High
9/28/2020Roth CapitalLower Price Target$11.00 ➝ $8.00High
9/28/2020Maxim GroupUpgradeHold ➝ Buy$20.00High
9/28/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$31.00 ➝ $12.00High
9/9/2020HC WainwrightReiterated RatingHoldHigh
8/11/2020Stifel NicolausLower Price Target$24.00 ➝ $16.00Medium
8/11/2020Cantor FitzgeraldLower Price Target$45.00 ➝ $31.00Medium
7/1/2020Roth CapitalDowngradeNeutral ➝ Sell$11.00High
7/1/2020Maxim GroupDowngradeBuy ➝ Hold$24.00High
6/30/2020BenchmarkReiterated RatingBuyHigh
6/29/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
6/26/2020Stifel NicolausDowngradeBuy ➝ Hold$19.00 ➝ $24.00High
6/23/2020Maxim GroupBoost Price Target$18.00 ➝ $24.00High
6/5/2020HC WainwrightReiterated RatingBuy$17.00Low
5/21/2020HC WainwrightReiterated RatingBuy$17.00Low
5/21/2020BenchmarkInitiated CoverageBuyHigh
5/13/2020Maxim GroupReiterated RatingBuy$18.00High
5/12/2020HC WainwrightReiterated RatingBuy$17.00High
4/30/2020Roth CapitalDowngradeBuy ➝ Neutral$13.00High
4/29/2020Stifel NicolausBoost Price TargetBuy$8.00 ➝ $19.00Medium
4/29/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$13.00 ➝ $17.00High
4/28/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $17.00Medium
4/17/2020HC WainwrightReiterated RatingBuy$13.00High
4/15/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $13.00Medium
4/7/2020HC WainwrightReiterated RatingBuyHigh
4/6/2020Royal Bank of CanadaDowngradeHoldHigh
3/27/2020Maxim GroupInitiated CoverageBuy$12.00High
3/13/2020Maxim GroupBoost Price TargetBuy$6.00 ➝ $12.00Low
3/13/2020Piper SandlerDowngradeOverweight ➝ Neutral$8.00High
3/13/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$7.00Low
3/4/2020Stifel NicolausReiterated RatingBuy$7.00High
3/3/2020HC WainwrightReiterated RatingBuy$13.00High
2/11/2020HC WainwrightReiterated RatingBuy$13.00Low
2/4/2020HC WainwrightReiterated RatingBuy$13.00Low
1/24/2020HC WainwrightReiterated RatingBuy$13.00High
1/23/2020Maxim GroupReiterated RatingBuyHigh
1/23/2020Royal Bank of CanadaReiterated RatingBuy$7.00High
1/6/2020Cantor FitzgeraldReiterated RatingOverweightN/A
1/3/2020HC WainwrightReiterated RatingBuy$13.00Medium
1/2/2020Piper Jaffray CompaniesLower Price TargetOverweight$10.00 ➝ $8.00High
12/19/2019Roth CapitalInitiated CoverageBuy$13.00High
11/14/2019Maxim GroupReiterated RatingBuyHigh
11/13/2019HC WainwrightReiterated RatingBuy$13.00High
9/18/2019HC WainwrightSet Price TargetBuy$13.00Low
9/16/2019CitigroupReiterated RatingBuy$7.00 ➝ $4.00Medium
8/11/2019Maxim GroupReiterated RatingBuy$6.00High
7/17/2019Piper Jaffray CompaniesLower Price TargetOverweight$12.00 ➝ $10.00High
6/11/2019HC WainwrightReiterated RatingBuy$13.00High
5/16/2019HC WainwrightInitiated CoverageBuy$13.00Medium
5/7/2019HC WainwrightReiterated RatingBuyHigh
4/22/2019HC WainwrightSet Price TargetBuy$13.00Low
4/3/2019Maxim GroupReiterated RatingBuy$8.00Medium
4/2/2019HC WainwrightSet Price TargetBuy$13.00High
3/25/2019Cantor FitzgeraldInitiated CoverageOverweight$12.00 ➝ $3.62Medium
3/22/2019HC WainwrightReiterated RatingBuy$13.00Medium
3/5/2019HC WainwrightSet Price TargetBuy$13.00High
2/20/2019Maxim GroupSet Price TargetBuy$8.00Low
1/25/2019HC WainwrightReiterated RatingBuy$13.00Medium
1/16/2019HC WainwrightSet Price TargetBuy$13.00High
1/15/2019Maxim GroupReiterated RatingBuy$8.00High
12/5/2018HC WainwrightInitiated CoverageBuy$13.00High
11/27/2018HC WainwrightSet Price TargetBuy$13.00Low
11/26/2018Maxim GroupSet Price TargetBuy$8.00Medium
11/12/2018HC WainwrightSet Price TargetBuy$13.00High
10/23/2018HC WainwrightSet Price TargetBuy$13.00Low
10/16/2018HC WainwrightSet Price TargetBuy$13.00High
10/9/2018HC WainwrightSet Price TargetBuy$13.00Low
10/2/2018Stifel NicolausInitiated CoverageBuy ➝ Buy$8.00High
9/18/2018HC WainwrightSet Price TargetBuy$13.00Low
8/16/2018Maxim GroupReiterated RatingBuy$8.00Low
8/15/2018HC WainwrightSet Price TargetBuy$13.00Medium
8/7/2018HC WainwrightSet Price TargetBuy$13.00Medium
5/21/2018Maxim GroupReiterated RatingBuy$8.00Medium
5/16/2018HC WainwrightSet Price TargetBuy$13.00Medium
5/10/2018HC WainwrightSet Price TargetBuy$13.00High
5/10/2018Maxim GroupSet Price TargetBuy$8.00High
4/12/2018HC WainwrightSet Price TargetBuy$13.00High
4/11/2018Maxim GroupSet Price TargetBuy$8.00Medium
3/21/2018HC WainwrightSet Price TargetBuy$13.00Low
3/15/2018Royal Bank of CanadaBoost Price TargetOutperform$11.00 ➝ $14.00High
3/15/2018HC WainwrightSet Price TargetBuy$13.00High
3/15/2018Maxim GroupSet Price TargetBuy$8.00High
2/15/2018Maxim GroupLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00Low
2/13/2018HC WainwrightSet Price TargetBuy$13.00Low
1/23/2018HC WainwrightSet Price TargetBuy$13.00High
1/12/2018HC WainwrightSet Price TargetBuy$13.00Medium
1/3/2018HC WainwrightSet Price TargetBuy$13.00High
1/2/2018Maxim GroupSet Price TargetBuy$12.00High
11/28/2017HC WainwrightSet Price TargetBuy$13.00Medium
11/9/2017HC WainwrightReiterated RatingBuy$13.00N/A
10/25/2017HC WainwrightSet Price TargetBuy$13.00N/A
10/18/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$11.00N/A
10/17/2017HC WainwrightSet Price TargetBuy$13.00N/A
10/6/2017HC WainwrightSet Price TargetBuy$13.00N/A
10/6/2017CitigroupInitiated CoverageBuy$10.00N/A
9/22/2017HC WainwrightReiterated RatingBuy$13.00Low
9/12/2017HC WainwrightReiterated RatingBuy$13.00Low
9/12/2017Maxim GroupReiterated RatingBuy$12.00Low
9/6/2017CitigroupInitiated CoverageBuy ➝ Buy$10.00High
8/9/2017HC WainwrightSet Price TargetBuy$13.00High
8/9/2017Maxim GroupSet Price TargetBuy$12.00High
7/27/2017HC WainwrightSet Price TargetBuy$13.00High
7/18/2017AegisReiterated RatingBuy$14.00Low
7/7/2017HC WainwrightSet Price TargetBuy$13.00Low
6/9/2017HC WainwrightReiterated RatingBuy$13.00Low
6/8/2017Maxim GroupSet Price TargetBuy$12.00High
6/8/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$14.00Medium
6/3/2017HC WainwrightSet Price TargetBuy$13.00Medium
6/1/2017Maxim GroupReiterated RatingBuy$12.00Low
5/28/2017HC WainwrightReiterated RatingBuy$13.00High
5/25/2017AegisBoost Price TargetBuy$11.00 ➝ $14.00Low
5/25/2017Stifel NicolausReiterated RatingBuy$11.00High
5/24/2017Maxim GroupBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.00High
5/17/2017AegisReiterated RatingBuy$11.00Low
5/11/2017HC WainwrightSet Price TargetBuy$13.00Low
5/11/2017Maxim GroupReiterated RatingBuyHigh
5/1/2017Nomura SecuritiesReiterated RatingBuy$40.00Low
5/1/2017Jefferies Financial GroupReiterated RatingNeutral$38.00Low
5/1/2017BNP ParibasReiterated RatingNeutral$39.00Low
4/25/2017Stifel NicolausReiterated RatingBuy$11.00High
3/21/2017AegisReiterated RatingBuyLow
3/16/2017HC WainwrightSet Price TargetBuy$13.00Medium
3/16/2017Maxim GroupUpgradeHold ➝ Buy$10.00High
3/16/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$13.00 ➝ $9.00High
2/24/2017HC WainwrightReiterated RatingBuy$13.00N/A
2/23/2017Maxim GroupReiterated RatingHoldN/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 5 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/19/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/18/2021
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/18/2021
  • 2 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
1/17/2022

Current Sentiment

  • 2 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Read More

Today's Range

Now: $4.75
Low: $4.51
High: $4.77

50 Day Range

MA: $6.13
Low: $4.61
High: $7.40

52 Week Range

Now: $4.75
Low: $4.47
High: $19.00

Volume

4,936,594 shs

Average Volume

4,138,110 shs

Market Capitalization

$999.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Inovio Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Inovio Pharmaceuticals in the last twelve months: Bank of America Co., HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for INO.

What is the current price target for Inovio Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Inovio Pharmaceuticals in the last year. Their average twelve-month price target is $12.20, suggesting a possible upside of 156.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting INO will reach $35.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $6.00 for Inovio Pharmaceuticals in the next year.
View the latest price targets for INO.

What is the current consensus analyst rating for Inovio Pharmaceuticals?

Inovio Pharmaceuticals currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INO, but not buy more shares or sell existing shares.
View the latest ratings for INO.

What other companies compete with Inovio Pharmaceuticals?

How do I contact Inovio Pharmaceuticals' investor relations team?

Inovio Pharmaceuticals' physical mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company's listed phone number is (267) 440-4200 and its investor relations email address is [email protected] The official website for Inovio Pharmaceuticals is www.inovio.com.